Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer.
AstraZeneca and Ionis's Wainua misses in Phase 3 heart trial CARDIO-TTRansform, likely due to overlap with Pfizer's Vyndamax; ...
Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed ...
Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across ...
Dimension Capital, an investment firm focused on the convergence of machine learning and life sciences, is raising its third batch of capital and seeking up to $750 million.
Amgen's Tezspire and Biokin's ADC post Phase 3 wins; Takeda exits China gene therapy deal; Gates Foundation backs ProFound on ...
Metriport raises $26M Series A led by Matrix to help doctors retrieve and prioritize patient data from across health systems.
Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in.
Pharma has much to learn from the surprising boom of telehealth sales of obesity drugs, Novo Nordisk’s CEO Mike Doustdar said at the Endpoints at #JPM26 event on the sidelines of the ...
Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s ...
MassBio report shows MA biopharma jobs fell 3.1%, NIH awards dropped 6%, while China's drug pipeline grew 36% in 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results